Please note: AABB reserves the right to make updates to this program.
Live Program Date: Tuesday, September 24, 2019 - On-Demand Available
Master Program Number: 19EL-479 (see program format numbers below under Registration)
After participating in this educational activity, participants should be able to:
In this program, the speakers will review four cases of septic transfusion reactions from apheresis platelets contaminated with Acinetobacter calcoaceticus-baumanni (and also Staphylococcus saprophyticus) which were recently reported in an MMWR. A description of each case, including the patient’s clinical course and investigation performed, will be presented by one of the Blood Center physicians involved in the investigation. A speaker from the Centers for Disease Control and Prevention (CDC) will also review the role the CDC played in the investigation including whole genome sequencing performed on the implicated organisms. Finally, information about additional Acinetobacter platelet contamination cases being investigated will be shared to the extent possible.
|Single Viewer: On-Demand||Register||19EL-479-4035|
|Group Viewing: On-Demand||Register||19EL-479-8035|
AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credits/contact hours for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Joy L. Fridey, MD, MBA, is the Regional Medical Director of the Southern California American Red Cross Blood Services (ARCBS). Her career includes extensive experience in blood center and hospital transfusion service settings where she has provided specialty expertise in adult and pediatric transfusion medicine, blood donor eligibility and screening, cellular therapies, and therapeutic apheresis. She was a study physician for 20 years in the NIH-funded Retrovirus Epidemiologic Donor Study. She was the lead investigator at a California blood center in a Phase III study of the INTERCEPT pathogen inactivation system which is now approved by the FDA for platelets and plasma. Dr. Fridey has twice chaired the AABB Donor History Questionnaire Task Force (DHQTF) and received the AABB Distinguished Service Award for her role in re-engineering the DHQ. She has chaired the AABB Standards Committee for Blood Banks and Transfusion services, served on the AABB Board of Directors, and is past president of the California Blood Bank Society. She is recognized as a Patient Blood Management (PBM) expert and chaired the AABB PBM Accreditation Committee. She is a member of the AABB Hemovigilance Committee and the international Alliance of Blood Operators. In addition to providing transfusion medicine consultancy services to approximately 130 hospitals, she was the Editor-in-Chief of the current (3rd) edition of the ARCBS “Compendium of Transfusion Practice Guidelines.” Currently, her major focus is bacterial contamination of platelets, and she will be presenting an oral abstract on an unusual septic transfusion reaction at the 2019 AABB Annual Meeting, and was a contributing author to two recent MMWRs on bacterial contamination of platelets. Dr. Fridey earned her medical degree from the Medical College of Pennsylvania (now the Drexel University College of Medicine), trained in Anatomic and Clinical Pathology at Temple University Hospital in Philadelphia, and completed her Fellowship in Blood Banking/Transfusion Medicine at Memorial Medical Center of Long Beach and the American Red Cross Blood Services. In 2000, she earned an MBA from the Peter F. Drucker Graduate School of Management at Claremont University in California.
Dr. Alison Laufer has worked in CDC’s Division of Healthcare Quality Promotion since 2013. She is the Associate Director of the Office of Scientific Innovation and Integration in the Clinical and Environmental Microbiology Branch of CDC’s Division of Healthcare Quality Promotion, and a Commander in the U.S. Public Health Service. Dr. Halpin leads a group of epidemiologists, laboratory scientists and bioinformaticians in leveraging next generation technologies and bioinformatics applications to better understand, prevent, and contain healthcare-associated infections; in investigations of healthcare-associated outbreaks, surveillance for and detection of novel antibiotic resistance mechanisms; and understanding and leveraging human and environmental microbial communities to improve patient safety. Dr. Halpin has studied the microbiome since 2004, completing her Bachelor of Science in Molecular and Cell Biology at the University of Connecticut, where she studied medicinal leech gut bacterial symbionts. She earned her doctorate from Yale University in Epidemiology of Microbial Diseases, with a focus on the relationship between the nasal microbiota and otitis media. From 2011 to 2013, she was an Epidemic Intelligence Service Officer in CDC’s Division of Foodborne, Waterborne, and Environmental Diseases.